A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of
two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to
Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).